Safety of revaccination with pneumococcal polysaccharide vaccine.

CONTEXT Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several years of first vaccination has been associated with a higher than expected frequency and severity of local injection site reactions. The risk of adverse events associated with revaccination of elderly and chronically ill persons 5 or more years after first vaccination, as is currently recommended, has not been well defined. OBJECTIVE To determine whether revaccination with PPV at least 5 years after first vaccination is associated with more frequent or more serious adverse events than those following first vaccination. DESIGN Comparative intervention study conducted between April 1996 and August 1997. PARTICIPANTS Persons aged 50 to 74 years either who had never been vaccinated with PPV (n = 901) or who had been vaccinated once at least 5 years prior to enrollment (n = 513). INTERVENTION PPV vaccination. MAIN OUTCOME MEASURES Postvaccination local injection site reactions and prevaccination concentrations of type-specific antibodies. RESULTS Those who were revaccinated were more likely than those who received their first vaccinations to report a local injection site reaction of at least 10.2 cm (4 in) in diameter within 2 days of vaccination: 11% (55/513) vs 3% (29/901) (relative risk [RR], 3.3; 95% confidence interval [CI], 2.1-5.1). These reactions resolved by a median of 3 days following vaccination. The highest rate was among revaccinated patients who were immunocompetent and did not have chronic illness: 15% (33/228) compared with 3% (10/337) among comparable patients receiving their first vaccinations (RR, 4.9; 95% CI, 2.4-9.7). The risk of these local reactions was significantly correlated with prevaccination geometric mean antibody concentrations. CONCLUSIONS Physicians and patients should be aware that self-limited local injection site reactions occur more frequently following revaccination compared with first vaccination; however, this risk does not represent a contraindication to revaccination with PPV for recommended groups.

[1]  M. Leinonen,et al.  Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. , 1997, Vaccine.

[2]  John W. Glasser,et al.  Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. , 1997, Pediatrics.

[3]  K. Nichol,et al.  Side effects associated with pneumococcal vaccination. , 1997, American journal of infection control.

[4]  R. Breiman,et al.  Prevention of pneumococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997 .

[5]  J. P. Davis,et al.  Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[6]  R. Snow,et al.  Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries? , 1995, Public health reports.

[7]  H. Konradsen,et al.  Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Quataert,et al.  Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S , 1995, Clinical and diagnostic laboratory immunology.

[9]  A. Detsky,et al.  Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. , 1994, Archives of internal medicine.

[10]  A. Lanier,et al.  Immunogenicity of pneumococcal revaccination in patients with chronic disease. , 1994, Archives of internal medicine.

[11]  D. Musher,et al.  Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Adair,et al.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. , 1991, The New England journal of medicine.

[13]  M. Mufson,et al.  Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. , 1991, Vaccine.

[14]  M. First,et al.  Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. , 1986, Archives of internal medicine.

[15]  S. Sarnaik,et al.  Revaccination with polyvalent pneumococcal vaccine in children with sickle cell anemia. , 1986, The American journal of pediatric hematology/oncology.

[16]  K. Edwards,et al.  Pneumococcal vaccine in normal children. Primary and secondary vaccination. , 1983, American journal of diseases of children.

[17]  J. Rigau-Pérez,et al.  Reactions to booster pneumococcal vaccination in patients with sickle cell disease , 1983, Pediatric infectious disease.

[18]  M. Hilleman,et al.  Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants , 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.